Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
Launch innovative vitamin sublingual sprays
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in Aptivate Champion Run
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Arco Lab now holds a 50% stake in Neviton
Subscribe To Our Newsletter & Stay Updated
